Biodesix Presents Data Showing Veristrat Useful for Identifying Avastin-Tarceva Responders | GenomeWeb

Biodesix last week presented results from a combined analysis of two Phase II trials using its Veristrat lung cancer companion diagnostic.

The results, which were shared at the Third European Lung Cancer Conference in Geneva, demonstrated that Veristrat was able to identify non-squamous non-small cell lung cancer patients likely to have better and worse survival outcomes when given combination therapy of bevacizumab – marketed by Roche as Avastin – and erlotinib – marketed by Roche as Tarceva.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

This week in Nature: Researchers describe the adaptation of organisms to environmental changes, while another study provides new insights into pig domestication.

The blog Sartorial Science seeks to challenge the stereotype of scientists as frumpy, messy, clueless dressers.

While one researcher says cloning the mammoth may be decades away, if successful, it may lead to a theme park of species that would no longer be extinct.

DNA Sequencing is being used by researchers in California to survey fish and marine life as part of a conservation effort.